» Articles » PMID: 37806461

Evolving Concepts in Helicobacter Pylori Management

Overview
Specialty Gastroenterology
Date 2023 Oct 8
PMID 37806461
Authors
Affiliations
Soon will be listed here.
Abstract

Helicobacter pylori is the most common chronic bacterial infection worldwide and the most significant risk factor for gastric cancer, which remains a leading cause of cancer-related death globally. H pylori and gastric cancer continue to disproportionately impact racial and ethnic minority and immigrant groups in the United States. The approach to H pylori case-finding thus far has relied on opportunistic testing based on symptoms or high-risk indicators, such as racial or ethnic background and family history. However, this approach misses a substantial proportion of individuals infected with H pylori who remain at risk for gastric cancer because most infections remain clinically silent. Moreover, individuals with chronic H pylori infection are at risk for gastric preneoplastic lesions, which are also asymptomatic and only reliably diagnosed using endoscopy and biopsy. Thus, to make a significant impact in gastric cancer prevention, a systematic approach is needed to better identify individuals at highest risk of both H pylori infection and its complications, including gastric preneoplasia and cancer. The approach to H pylori eradication must also be optimized given sharply decreasing rates of successful eradication with commonly used therapies and increasing antimicrobial resistance. With growing acceptance that H pylori should be managed as an infectious disease and the increasing availability of susceptibility testing, we now have the momentum to abandon empirical therapies demonstrated to have inadequate eradication rates. Molecular-based susceptibility profiling facilitates selection of a personalized eradication regimen without necessitating an invasive procedure. An improved approach to H pylori eradication coupled with population-level programs for screening and treatment could be an effective and efficient strategy to prevent gastric cancer, especially in minority and potentially marginalized populations that bear the heaviest burden of H pylori infection and its complications.

Citing Articles

Assessment of the bidirectional causal association between Helicobacter pylori infection and allergic diseases by mendelian randomization analysis.

Fan G, Duan B, Xin F, Qu Z Sci Rep. 2025; 15(1):5746.

PMID: 39962134 PMC: 11832746. DOI: 10.1038/s41598-025-89981-3.


Potassium-Competitive Acid Blockers and Proton Pump Inhibitors: The Dynamic Duo of Acid Blockers.

Ketchem C, Lynch K Gastroenterol Hepatol (N Y). 2025; 20(12):733-738.

PMID: 39886002 PMC: 11776008.


Hp eradication decreased the expression level of PG II in patients of Hp negative with gastric intestinal metaplasia: a retrospective cross-sectional study.

Wang Y, Cao X, Shan B, Chen S, Li S, Fei S J Health Popul Nutr. 2025; 44(1):20.

PMID: 39856761 PMC: 11762886. DOI: 10.1186/s41043-025-00756-y.


Review of Methods for Detection in Kazakhstan.

Alyona L, Aizhan S, Aidana T, Alexey S, Yekaterina Y JGH Open. 2025; 9(1):e70101.

PMID: 39830988 PMC: 11740085. DOI: 10.1002/jgh3.70101.


Helicobacter pylori infection promotes M1 macrophage polarization and gastric inflammation by activation of NLRP3 inflammasome via TNF/TNFR1 axis.

Fei X, Chen S, Li L, Xu X, Wang H, Ke H Cell Commun Signal. 2025; 23(1):6.

PMID: 39762835 PMC: 11705855. DOI: 10.1186/s12964-024-02017-7.


References
1.
Fendrick A, Chernew M, Hirth R, Bloom B, Bandekar R, Scheiman J . Clinical and economic effects of population-based Helicobacter pylori screening to prevent gastric cancer. Arch Intern Med. 1999; 159(2):142-8. DOI: 10.1001/archinte.159.2.142. View

2.
Davies R, Crabbe D, Roderick P, Goddard J, Raftery J, Patel P . A simulation to evaluate screening for Helicobacter pylori infection in the prevention of peptic ulcers and gastric cancers. Health Care Manag Sci. 2002; 5(4):249-58. DOI: 10.1023/a:1020326005465. View

3.
Yan L, Chen Y, Chen F, Tao T, Hu Z, Wang J . Effect of Helicobacter pylori Eradication on Gastric Cancer Prevention: Updated Report From a Randomized Controlled Trial With 26.5 Years of Follow-up. Gastroenterology. 2022; 163(1):154-162.e3. DOI: 10.1053/j.gastro.2022.03.039. View

4.
Sugano K, Spechler S, El-Omar E, McColl K, Takubo K, Gotoda T . Kyoto international consensus report on anatomy, pathophysiology and clinical significance of the gastro-oesophageal junction. Gut. 2022; 71(8):1488-1514. PMC: 9279854. DOI: 10.1136/gutjnl-2022-327281. View

5.
Karimi P, Islami F, Anandasabapathy S, Freedman N, Kamangar F . Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev. 2014; 23(5):700-13. PMC: 4019373. DOI: 10.1158/1055-9965.EPI-13-1057. View